LI
NBIX icon

LRI Investments’s Neurocrine Biosciences NBIX Stock Holding History

LRI Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.91K Buy
41
+5
+14% +$742 ﹤0.01% 1071
2026
Q1 		$4.74K Buy
+36
New +$4.78K ﹤0.01% 1103

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

LRI Investments's NBIX Position: Q2 2026 in Review

LRI Investments increased its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, buying an estimated $742 and bringing the position to 41 shares worth $6.91K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

LRI Investments first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • LRI Investments held 41 shares of Neurocrine Biosciences worth $6.91K as of Q2 2026.
  • LRI Investments bought 5 Neurocrine Biosciences shares in Q2 2026, an estimated $742.
  • Neurocrine Biosciences made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1071 holding.
  • LRI Investments first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.